Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND

As Previously Announced, Reldesemtiv Had No Effect on the Primary Endpoint of Change from Baseline in ALSFRS-R or Key Secondary Endpoints Trial Discontinued…

Related Keywords

,Site Personnel ,Reldesemtiv Had No Effect ,Primary Endpoint ,Key Secondary ,Futility Following Second Planned Interim ,Reveals Site Personnel ,Patients Have Favorable View ,Trial Features ,Reduce Burden ,News ,Ggregator ,Reaking News ,Uration ,Media ,